Among them is gemcitabine, a pyrimidine antimetabolite. 13–17 Gemcitabine is well tolerated and can be safely used in patients with impaired renal function (GFR ≥ 30 mL/min). 18 Trial history and ...

Gemcitabine, a drug with established efficacy against a number of solid tumors, has therapeutic limitations due to its rapid metabolic inactivation. The aim of this study was the development of an ...

The crystal structure of the geranylgeranyl diphosphate synthase from Sinapis alba (mustard) has been solved in two crystal forms at 1.8 and 2.0 Å resolutions. In one of these forms, the dimeric ...

Gemcitabine (0.01 µM) induced a cell apoptosis of 12 ± 1%, 0.1 µM of OxA induced a cell apoptosis of 13 ± 1%, and the combination of these two compounds induced a cell apoptosis of 15 ± 1% . It should ...

A phase 2 trial in PAC demonstrated the safety and preliminary efficacy of TTFields therapy with gemcitabine with or without nab-paclitaxel. We report final data from PANOVA-3 (NCT03377491), the ...

We evaluated whether regional nodal irradiation improves outcomes in patients with biopsy-proven, node-positive breast cancer who reach ypN0 status after neoadjuvant chemotherapy.

In the 260-patient study, median event-free survival reached 16 months for patients assigned to PAXG, as compared with 10.2 months with the mFOLFIRINOX (5-fluorouracil, leucovorin, irinotecan ...